Matinas Biopharma Holdings Inc (MTNB)

[The Lawman]

Perhaps it's just me, but I will take the word of Dr. Kastelein, perhaps the world's foremost authority on lipid cardiology, over paid bashers and shorts.

According to Dr. Kastelein, the most significant factor lipid factor in reducing cardiac events (CE) is the level of EPA in the blood.

On this count, MAT 9001 again handily bested Vascepa for the second time.

Moreover, in the per protocol (PP) group, MAT 9001 showed clinically significant improvement over Vascepa in reducing triglycerides, along with many other lipid markers. This is especially significant as the PP group consists of those patients who actually took the drug as prescribed rather than those who are less careful about doing so.

Presumably, if a patient does to the trouble of getting a prescription for MAT 9001, he/she would take it as prescribed. If so, he/she will have much higher EPA blood levels, and much lower triglycerides than if he/she had taken Vascepa.

More significantly, given the higher level of EPA in the blood, it stands to reason those patients taking MAT 9001 will have a significantly greater reduction in cardiac events than the 25% reduction in CE shown for those patients taking Vascepa.

My opinions, of course, but they would seem to be supported by the trials to date, along with the opinions of prominent scientists and cardiologists, including Dr. Kastelein.